M.Yu. Reutovich ¹, O.V. Krasko ², A.V. Ivanov ³

1. State Educational Establishment «Belarusian Medical Academy of Postgraduate Education,» Minsk, Belarus;
2. United Institute of Informatics Problems, National Academy of Sciences of Belarus, Minsk, Belarus;
3. N.N. Alexandrov National Cancer Center of Belarus, Minsk, Belarus

DOI: https://www.doi.org/10.52532/2663-4864-2023-1-67-30-35

UDC: 616.33-006.6-085.28

Year: 2023 issure: 67 number: 1 pages: 30-35

Download PDF:

ABSTRACT

Relevance: Given the high biological aggressiveness of infiltrative gastric cancer warranting a need for a multimodal approach to its radical treatment employing adjuvant perfusion thermochemotherapy (HIPEC) and systemic adjuvant polychemotherapy, the goal of the present study was to assess the efficacy and expediency of such an approach.
The study aimed to evaluate the effectiveness of a combination of HIPEC and systemic adjuvant polychemotherapy in patients radically operated on for infiltrative forms of gastric cancer pT4a-bN0-3M0.
Methods: The study examined the long-term results of radical treatment for gastric cancer in 141 patients (pT4a-bN0-3M0, Borrmann type III-IV). Of them, 18 patients underwent a multimodal treatment, including radical surgery in combination with HIPEC and systemic adjuvant polychemotherapy (ACT) (oxaliplatin 100 mg/m2 (on day 1 of the cycle), capecitabine 1,000 mg/m2 or tegafur 10-15 mg/kg (2 times per day, on days 1-14 of the cycle, with a 7-day break between cycles, 8 cycles) – HIPEC/ACT group. For comparison purposes, we used the data on 55 radically operated patients (surgery control) and 68 other patients who underwent radical surgery in combination with HIPEC (cisplatin 50 mg/m2 + doxorubicin 50 mg/m2, 420C, one hour). The long-term treatment results were evaluated using competing risks analysis, the Kaplan-Meier multiplier method, and multivariate analysis (Cox and Fine-Gray models).
Results: The multimodal treatment group showed a decrease in unfavorable outcomes associated with tumor progression – β = -2.14;
RR 0.12 (95% CI 0.04-0.38), р<0.001, as well as a decrease in the risk of carcinomatosis – β = -1.99; RR 0.14 (95% CI 0.04-0.44), р<0,001; and improvement in 5-year survival rates (as compared with the control groups), viz.: adjusted survival – 81.9±9.5% (р=0.003); progression-free survival – 82.2±9.3% (р<0.001); and dissemination-free survival – 81.9±9.5% (р<0.001).
Conclusion: It is advisable to supplement the standard approach for infiltrative gastric cancer (radical surgery and systemic polychemotherapy) with perfusion HIPEC to prolong the remission of the tumor process.
Keywords: gastric cancer, adjuvant hyperthermic intraperitoneal chemotherapy (AHIPEC), adjuvant systemic polychemotherapy (ACT).

List of sources used:
1. Zhang J.F., Lv L., Zhao S., Zhou Q., Jiang C.G. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages // Ann. Surg. Oncol. – 2022. – Vol. 29, № 5. – Р. 3170–3186. https://doi.org/10.1245/s10434-021-11316-z
2. Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial // Lancet. – 2019. – Vol. 393(10184). – P. 1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1
3. Kim I.H., Park S.S., Lee C.M., Kim M.C., Kwon I.K., Min J.S., Kim H.I., Lee H.H., Lee S.I., Chae H. Efficacy of adjuvant S-1 versus XELOX chemotherapy for patients with gastric cancer after D2 lymph node dissection: a retrospective, multi-center observational study // Ann. Surg. Oncol. – 2018. – Vol. 25, № 5. – Р. 1176–1183. https://doi.org/10.1245/s10434-018-6375-z
4. Dominic J.L., Kannan A., Tara A., Hakim Mohammed A.R., Win M., Khorochkov A., Sultan W., Ahmed A., Kantamaneni K., Syzmanski M.W., Singh R., Marquez R.A., Asarian A., Thirunavukarasu P., Keckeisen G. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for the prevention and control of peritoneal metastasis in patients with gastrointestinal malignancies: a systematic review of randomized controlled trials // EXCLI J. – 2021. – Vol. 20. – P. 1328–1345. https://doi.org/10.17179/excli2021-4108
5. Ревтович М.Ю. Результаты использования комбинации перфузионной термохимиотерапии с адъювантной системной полихимиотерапией у пациентов с резектабельным раком желудка pT4a-bN0-3M0 // Поволжский онколог. вестн. – 2020. – Т. 11, № 1. – С. 32–41. [Revtovich M.YU. Rezul’taty ispol’zovaniya kombinacii perfuzionnoj termohimioterapii s ad»yuvantnoj sistemnoj polihimioterapiej u pacientov s rezektabel’nym rakom zheludka pT4a-bN0-3M0 // Povolzhskij onkologicheskij vestnik– 2020. – Т. 11, № 1. – S. 32–41.] http://oncovestnik.ru/none/rezultaty-ispolzovaniya-kombinatsii-perfuzionnoj-termokhimioterapii-s-ad-yuvantnoj-sistemnoj-polikhimioterapiej-u-patsientov-s-rezektabelnym-rakom-zheludka-pt4a-bn0-3m0/
6. Ревтович М.Ю., Красько О.В., Малькевич В.Т. Результаты комплексного лечения рака желудка pT4a-bN0-3M0 // Евразийский онколог. журн. – 2021. – Т. 9, № 2. – С. 101–112. [Revtovich M.YU., Kras’ko O.V., Mal’kevich V.T. Rezul’taty kompleksnogo lecheniya raka zheludka pT4a-bN0-3M0 // Evrazijskij onkologicheskij zhurnal – 2021. – Т. 9, № 2. – S. 101–112] https://recipe.by/wp-content/uploads/2021/07/YEL_2_2021_EOZH_RB_Rezultaty-kompleksnogo-lecheniya-raka-zheludka-pT4a-bN0-3M0.pdf
7. Ревтович М.Ю., Красько О.В., Малькевич В.Т., Потейко А.И. Результаты радикального лечения инфильтративных форм рака желудка с применением перфузионной термохимиотерапии // Евразийский онколог. журн. – 2022. – Т. 10, № 2. – С. 107–117. [Revtovich M.YU., Kras’ko O.V., Mal’kevich V.T., Potejko A.I. Rezul’taty radikal’nogo lecheniya infil’trativnyh form raka zheludka s primeneniem perfuzionnoj termohimioterapii // Evrazijskij onkologicheskij zhurnal. – 2022. – Т. 10, № 2. – S. 107–117] https://recipe.by/wp-content/uploads/2022/07/107-117_eog-2-2022-t10.pdf
8. Reutovich M.Yu., Krasko O.V., Sukonko O.G. Hyperthermic intraperitoneal chemotherapy in serosa-invasive gastric cancer patients // Eur. J. Surg. Oncol. – 2019. – Vol. 45, № 12. – Р. 2405-2411. https://doi.org/10.1016/j.ejso.2019.07.030
9. Kuk D., Varadhan R. Model selection in competing risks regression // Stat. Med. – 2013. – Vol. 32, № 18. – Р. 3077–3088. https://doi.org/10.1002/sim.5762
10. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk // J. Amer. Stat. Assoc. – 1999. – Vol. 94(446) – Р. 496–509.
11. Therneau, T., Grambsch, P. Modeling Survival Data: Extending the Cox Model. – Springer-Verlag, 2000. – 350p. https://doi.org/10.1007/978-1-4757-3294-8
12. R Core Team. R: A language and environment for statistical computing. – R Foundation for Statistical Computing, Vienna, Austria, 2022. https://www.R-project.org/. 20.03.2023
13. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-7. http://CRAN.R-project.org/package=cmprsk. 18.11.2022
14. Deng J., Liu J., Wang W., Sun Z., Wang Z., Zhou Z., Xu H., Liang H. Validation of clinical significance of examined lymph node count for accurate prognostic evaluation of gastric cancer for the eighth edition of the American joint committee on cancer (AJCC) TNM staging system // Chin. J. Cancer Res. – 2018. – Vol. 30, № 5. – Р. 477-491. https://doi.org/10.21147/j.issn.1000-9604.2018.05.01
15. Ji Z.H., Zhang Y., Li Y. Intra-operative hyperthermic intraperitoneal chemotherapy for prevention and treatment of peritoneal metastases from gastric cancer: a narrative review // J. Gastrointest. Oncol. – 2021. – Vol. 12 (Suppl. 1) – Р. 70-78. https://doi.org/10.21037/jgo-20-262
16. Zhang J.F., Lv L., Zhao S., Zhou Q., Jiang C.G. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages // Ann. Surg. Oncol. – 2022. – Vol. 29, № 5. – Р. 3170-3186. https://doi.org/10.1245/s10434-021-11316-z